United States Patent 9,157,121: Iloperidone Pharmacogenomic Dosing Claims and Patent Landscape
U.S. Patent No. 9,157,121 protects genotype-guided dosing of iloperidone, including Fanapt, based primarily on a KCNQ1 marker associated with QT-interval prolongation. The patent does not broadly claim iloperidone, schizophrenia treatment, or ordinary 24 mg/day dosing. Its commercial scope depends on whether a treatment provider or diagnostic workflow determines the patient’s KCNQ1 genotype and adjusts the iloperidone dose accordingly.
The strongest independent-claim coverage is directed to:
- Testing or determining KCNQ1 position 78927.
- Treating CC patients with a lower iloperidone quantity.
- Treating non-CC patients with a higher quantity.
- Using iloperidone or a specified active metabolite.
- In some claims, incorporating CYP2D6 genotype information.
- Treating patients with long QT syndrome under a genotype-based dosing protocol.
The patent is a method-of-treatment patent. It is not a composition patent, formulation patent, or manufacturing patent.
What does U.S. Patent 9,157,121 claim?
The patent’s independent claims are claims 1, 8, and 12. Each uses a different characterization of the pharmacogenomic dosing method.
| Claim |
Principal subject matter |
Key limitation |
| 1 |
Genotype-guided iloperidone administration |
KCNQ1 position 78927; CC receives less than non-CC |
| 8 |
Expression-product-based treatment |
Characterized KCNQ1 expression product corresponds to CC or non-CC |
| 12 |
Treatment of a patient with LQTS |
Dose is selected based on KCNQ1 genotype |
Claim 1: direct KCNQ1 genotype testing
Claim 1 requires determining, or having determined, the patient’s KCNQ1 genotype at position 78927 of the disclosed sequence. It then divides patients into two groups:
- CC genotype: associated with increased QT-prolongation risk and treated with a first, lower quantity.
- Non-CC genotype: treated with a second, higher quantity.
The claim requires that the first quantity be less than the second quantity. This relative-dose limitation is central. A protocol that tests KCNQ1 but gives the same dose to both genotype groups would not satisfy the literal requirements of claim 1.
The claim covers iloperidone and “a metabolite thereof.” Claim 2 narrows the method to iloperidone itself. Claim 3 identifies a particular metabolite:
1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]ethanol.
Claim 6 specifies 24 mg/day as the second, higher quantity. Because claim 6 depends on claim 1, the 24 mg/day dose must be administered to the non-CC group, while the CC group receives a lower dose.
Claim 8: expression-product characterization
Claim 8 substitutes characterization of a KCNQ1 gene expression product for direct genotype determination. The method remains divided into:
- A CC-corresponding expression product, followed by the lower quantity.
- A non-CC-corresponding expression product, followed by the higher quantity.
This language may reach workflows that infer genotype or genotype status from a molecular expression product rather than requiring a conventional allele-specific genotyping assay. The claim still requires genotype correspondence to the CC or non-CC categories and a lower-versus-higher dose relationship.
Claim 12: long QT syndrome
Claim 12 is directed to an individual suffering from long QT syndrome. It requires determining the KCNQ1 genotype and administering a quantity based on that genotype.
Unlike claim 1, claim 12 does not expressly state in the quoted language that the first quantity must be less than the second quantity. It requires separate first and second quantities tied to CC and non-CC status. This difference may affect claim construction and infringement analysis.
The LQTS limitation narrows claim 12’s patient population. A patient treated for schizophrenia without documented LQTS would not satisfy the express patient-condition limitation of claim 12, although the same treatment could implicate claims 1 or 8.
What do the dependent claims add?
Claims 2 through 7 narrow claim 1. Claims 9 through 11 narrow claim 8. Claims 13 through 15 narrow claim 12.
| Claims |
Added limitation |
| 2 |
Iloperidone itself |
| 3 |
Specified iloperidone metabolite |
| 4 |
CYP2D6 genotype information combined with KCNQ1 status |
| 5 |
Listed psychiatric or neurologic conditions |
| 6 |
Second quantity is 24 mg/day |
| 7 |
Non-CC genotype is AC or AA |
| 9 |
Characterization of CYP2D6 expression product |
| 10 |
Second quantity is 24 mg/day |
| 11 |
Non-CC genotype is AC or AA |
| 13 |
CYP2D6 polymorphism is CYP2D6G1846A or CYP2D6C100T |
| 14 |
Second quantity is 24 mg/day |
| 15 |
Non-CC genotype is AC or AA |
Claim 7 narrows “non-CC” to AC or AA. In a conventional biallelic interpretation, this excludes the possibility that a non-CC genotype could include an unspecified alternative genotype. It also makes the claim more vulnerable to design-around strategies that use a different genetic classification or a different KCNQ1 marker.
How does the CYP2D6 limitation affect patent scope?
Claim 4 introduces a combined pharmacogenomic protocol using KCNQ1 and CYP2D6.
The claim identifies:
- CYP2D6G1846A genotypes AA or GA.
- CYP2D6C100T genotypes TT or CT.
- CYP2D6G1846A genotype GG.
- CYP2D6C100T genotype CC.
The lower-dose branch requires the specified CYP2D6 risk genotype together with KCNQ1 CC. The higher-dose branch requires the specified CYP2D6 non-risk genotype together with KCNQ1 non-CC.
This creates a conjunctive limitation. A protocol that uses KCNQ1 alone may fall within claim 1 but not claim 4. A protocol that tests CYP2D6 without testing KCNQ1 would not meet claim 4. The patent therefore has layered coverage:
- KCNQ1-only dosing.
- KCNQ1 dosing combined with CYP2D6 status.
- Expression-product characterization instead of direct genotype testing.
- A distinct LQTS population.
The CYP2D6 language also creates potential technical and claim-construction issues. The claim refers to specific nucleotide substitutions and genotype labels, but commercial pharmacogenomic testing commonly reports CYP2D6 star alleles and metabolizer phenotypes. A test reporting only poor, intermediate, normal, or ultrarapid metabolizer status may not literally report the claimed nucleotide genotype.
What is the patent’s therapeutic and technical scope?
The disclosed invention is directed to reducing iloperidone-associated QT-prolongation risk by using genetic information to select dose. The core technical relationship is:
| Genetic status |
Claimed clinical interpretation |
Claimed dosing consequence |
| KCNQ1 CC at position 78927 |
Increased QT-prolongation risk |
Lower iloperidone quantity |
| KCNQ1 AC or AA |
Not associated with increased risk |
Higher iloperidone quantity |
| Non-CC generally |
Not associated with increased risk |
Higher iloperidone quantity |
Claim 5 expands the therapeutic context to schizophrenia, schizoaffective disorder, depression, bipolar mania or depression, psychotic disorders, delusional disorder, schizophreniform disorder, Tourette’s syndrome, cardiac arrhythmia, and related conditions.
The condition list does not convert the patent into a broad treatment patent. Each listed condition remains tied to the genotype-based administration method of claim 1.
What patents protect Fanapt and iloperidone?
Iloperidone has several distinct patent categories. They should not be treated as a single patent estate.
| Patent category |
Typical subject matter |
Relevance to U.S. 9,157,121 |
| Compound patents |
Iloperidone molecule and related chemical compounds |
Separate from 9,157,121 |
| Formulation patents |
Tablets, dosage forms, release characteristics, excipients |
Separate from 9,157,121 |
| Method-of-treatment patents |
Psychiatric or neurologic treatment |
May overlap commercially |
| Pharmacogenomic patents |
Genotype-based dose selection |
Core subject of 9,157,121 |
| Manufacturing patents |
Chemical synthesis, intermediates, purification |
Separate from 9,157,121 |
| Regulatory exclusivity |
FDA new-drug or other exclusivity |
Separate from patent rights |
U.S. Patent 9,157,121 does not claim the chemical composition of iloperidone. A generic manufacturer could potentially obtain approval for iloperidone while still facing method-of-use exposure if its labeling, promotional activity, or distribution strategy encourages genotype-directed dosing covered by the patent.
The most relevant family member is U.S. Patent No. 8,586,610, which covers related iloperidone pharmacogenomic subject matter. U.S. Patent No. 9,157,121 is a continuation-type patent in the same broader family and should be analyzed with the earlier patent for double-patenting, prosecution-history, and terminal-disclaimer issues. The exact relationship and expiration date must be taken from the USPTO Patent Center record for both patents.[1]
When does U.S. Patent 9,157,121 lose exclusivity?
The patent’s enforceable term is governed by the earliest effective nonprovisional filing date, adjusted for patent-term adjustment and any terminal disclaimer. The issue date, October 13, 2015, does not establish the expiration date.[1]
The family is associated with a late-2000s priority period. The nominal patent term therefore falls in the late 2020s, subject to:
- Patent-term adjustment.
- Any terminal disclaimer over an earlier family patent.
- Patent-term extension, if available and granted.
- Continuation-family term calculations.
- Correct identification of the earliest effective nonprovisional filing.
The practical commercial question is not simply whether U.S. Patent 9,157,121 remains unexpired. A generic entrant must evaluate all unexpired patents listed for the relevant Fanapt product, including formulation, method-of-use, and later continuation patents.
What is the Orange Book status of U.S. Patent 9,157,121?
The Orange Book status must be evaluated against the specific listed drug and patent listing history. FDA listing does not establish that every claim is valid or infringed. It indicates that the NDA holder submitted the patent for listing under the FDA’s patent-listing framework.[2]
For Fanapt, the relevant analysis should compare:
- The Orange Book patent-use code.
- The listed patent expiration date.
- Whether the patent is listed against all strengths or only specified uses.
- Whether a later patent was submitted after the original NDA approval.
- Whether the patent has been delisted, corrected, or withdrawn.
- Whether a generic applicant filed a Paragraph IV certification.
Because 9,157,121 is a method-of-use patent, its Orange Book relevance depends heavily on the use code. A use code directed to genotype-guided dosing would be narrower than a use code covering treatment of schizophrenia generally.
Which companies are most exposed to this patent?
The direct commercial exposure falls on companies that do one of the following:
- Market iloperidone or Fanapt with labeling that recommends KCNQ1-guided dosing.
- Sell or distribute a diagnostic-linked treatment protocol.
- Encourage providers to test KCNQ1 position 78927 before selecting an iloperidone dose.
- Promote a 24 mg/day regimen for non-CC patients while recommending a lower dose for CC patients.
- Provide an integrated pharmacogenomic service that includes KCNQ1 and CYP2D6 testing.
A generic company seeking a conventional iloperidone approval may avoid direct method-of-use exposure through a skinny label that omits the patented pharmacogenomic use, provided the omitted use is legally separable and the company does not induce infringement through marketing or other conduct. FDA labeling constraints and induced-infringement law make the product label only one part of the analysis.
What Paragraph IV challenges and litigation risks exist?
A Paragraph IV certification would assert that the listed patent is invalid, unenforceable, or not infringed. For this patent, likely challenge positions would include:
- Lack of written description for the specific KCNQ1 marker or genotype-to-dose relationship.
- Enablement concerns involving clinical implementation across patient populations.
- Obviousness based on known QT-prolongation risk, pharmacogenomics, and iloperidone dosing.
- Ineligible subject matter arguments directed to a natural genetic relationship combined with conventional testing and treatment steps.
- Noninfringement based on omission of KCNQ1 testing from the label.
- Noninfringement based on use of different genetic markers or metabolizer categories.
- Failure to satisfy the exact lower-dose and higher-dose relationship.
- Failure to satisfy the LQTS or CYP2D6 limitations in narrower claims.
A patent-holder suit triggered by a Paragraph IV notice would ordinarily invoke the Hatch-Waxman 30-month stay if the statutory requirements are met. The principal risk is therefore claim-specific. A generic may avoid claims 4, 8, or 12 while still litigating claim 1, or it may avoid the patent through a label that excludes the covered pharmacogenomic use.
How strong is the patent estate?
The estate is strongest where a defendant’s conduct closely follows the claim language:
- The provider tests KCNQ1 position 78927.
- The test identifies CC versus non-CC.
- The provider administers less drug to CC patients.
- The provider administers 24 mg/day or another higher dose to non-CC patients.
- The protocol is documented in the label, treatment software, clinical pathway, or promotional materials.
The estate is weaker where treatment is conventional and genotype-blind. It is also weaker where a defendant uses:
- A different KCNQ1 marker.
- A polygenic risk score.
- A clinical QT measurement rather than genotype.
- CYP2D6 phenotype alone.
- A uniform dose.
- A label that omits genotype-guided dosing.
- A different iloperidone metabolite or non-iloperidone antipsychotic.
The patent’s commercial value therefore depends more on adoption of pharmacogenomic prescribing than on the volume of ordinary iloperidone prescriptions.
What generic launch scenarios are plausible?
| Scenario |
Patent impact |
| Full iloperidone label with genotype-guided dosing |
Highest infringement and litigation risk |
| Skinny label excluding genotype-guided dosing |
Lower risk, subject to inducement analysis |
| Label limited to psychiatric indications without LQTS |
May avoid claim 12 but not necessarily claims 1 or 8 |
| No KCNQ1 testing or recommendation |
Stronger noninfringement position |
| CYP2D6-only testing |
Likely avoids KCNQ1-dependent claims |
| Alternative dose algorithm |
Requires analysis of the “first quantity less than second quantity” limitation |
| Launch after all relevant patents expire |
Lowest patent risk |
Key Takeaways
- U.S. Patent 9,157,121 is a pharmacogenomic method patent, not an iloperidone composition patent.
- Its central limitation is dose selection based on KCNQ1 position 78927.
- CC patients receive the lower quantity; non-CC patients receive the higher quantity.
- Claims 4, 9, and 13 add CYP2D6 genotyping or expression-product analysis.
- Claims 6, 10, and 14 identify 24 mg/day as the higher dose.
- Claim 12 is limited to patients with long QT syndrome.
- A conventional generic iloperidone label may avoid infringement if it omits the patented genotype-guided use, but promotional conduct can create induced-infringement risk.
- The patent must be analyzed with U.S. Patent 8,586,610 and other Fanapt formulation, use, and continuation patents.
- The effective expiration date depends on the family’s earliest nonprovisional filing, patent-term adjustment, and any terminal disclaimer.
- The commercial strength of the patent depends on whether KCNQ1-guided prescribing becomes part of the approved label or clinical workflow.
FAQs
Does U.S. Patent 9,157,121 cover all uses of Fanapt?
No. It covers specified genotype-guided administration methods. Ordinary Fanapt treatment without the claimed KCNQ1-based dose selection is outside the literal scope of the independent claims.
Can a generic sell iloperidone without performing KCNQ1 testing?
Potentially, if its approved labeling and conduct do not encourage the patented genotype-guided use. The analysis depends on the final label, marketing activity, and applicable induced-infringement law.
Is KCNQ1 CC the same as a diagnosis of long QT syndrome?
No. The patent treats KCNQ1 CC at the specified position as associated with increased QT-prolongation risk. Claim 12 separately requires a patient suffering from LQTS.
Does a 24 mg/day iloperidone dose alone infringe the patent?
Not necessarily. Claims 6, 10, and 14 require the genotype-based limitations of their respective independent claims. A 24 mg/day dose without the claimed genetic workflow does not automatically satisfy those claims.
Are CYP2D6 test results alone sufficient to practice the patented method?
No. The CYP2D6-dependent claims also require the specified KCNQ1 status and the corresponding dose-selection steps.
References
-
United States Patent and Trademark Office. (2015). U.S. Patent No. 9,157,121, methods of treating patients with iloperidone based on genetic markers. USPTO Patent Center.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2009). Fanapt (iloperidone) prescribing information. FDA.
-
United States Patent and Trademark Office. (2013). U.S. Patent No. 8,586,610, methods of treating patients with iloperidone based on genetic markers. USPTO Patent Center.
-
35 U.S.C. §§ 154, 271, 355. United States Code.
